Sanofi Sa · EURONEXT:SAN
Sanofi Sa — Q3 2020 Earnings Presentation
6 slides from Sanofi Sa's earnings presentation, Oct 29, 2020
Slide 1: R&D appendices - Q3 2020 Results
R&D appendices Q3 2020 Results October 29, 2020
Slide 2: R&D Pipeline – Phase III & Registration
R&D Pipeline – Phase III & Registration Phase III Registration Name Description Indication Name Description Indication Libtayo®(1) Anti-PD-1 mAb monotherapy 1L NSCLC Sarclisa® Anti-CD38 mAb 2L RRMM (IKEMA) Libtayo®(1) Anti-PD-1 mAb + chemotherapy 1L NSCLC Dupixent®(1) Anti-IL4/IL13 mAb AD 6 – 11 yea
Slide 3: R&D Pipeline – Phase I & II
R&D Pipeline – Phase I & II Phase I Phase II Name Description Indication Name Description Indication SAR439459 anti-TGFb mAb Advanced Solid Tumors R Amcenestrant(1) SERD Metastatic Breast Cancer 2/3L Amcenestrant(1) SERD + palbociclib Metastatic Breast Cancer Amcenestrant(1) SERD Early Breast Cancer
Slide 4: Expected submission timelines
Expected submission timelines(1) Amcenestrant(4) 2/3L mBC olipudase alfa SP0253(5) rilzabrutinib venglustat romilkimab Dupixent®(3) NMEs ASMD(7) ad+ped COVID-19 Pemphigus ADPKD(9) Systemic Scleroderma Bullous pemphigoid fitusiran mRNA vaccine(6) SAR408701 BIVV001(**)(8) itepekimab(3) Tolebrutinib(10
Slide 5: 2021 – significant year for Sanofi’s pipeline ahead
2021 – significant year for Sanofi’s pipeline ahead Expected pivotal results(1) Expected Phase 2 readouts(1) • Amcenestrant (AMEERA-3) 2L/3L in mBC • Venglustat GBA PD • Fitusiran for Hemophilia A & B • Sarclisa® subcutaneous formulation • BIVV001(2) for Hemophilia A • Amcenestrant, early BC, AMEERA
Slide 6: Accelerating global COVID-19 vaccine availability
Accelerating global COVID-19 vaccine availability Target Platform Expected timeline Annual capacity 2020 2021 H2 H1 H2 September End H1 Phase 1/2 start Earliest (>400 patients) approval Baculovirus including 1bn 1 recombinant December possible doses(3) approach(1) Preliminary EUA(2) Phase 1/2 data &